Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis

Inclusion Criteria: * Sign Informed Consent * Use of condom by sexually active males for the entire duration of the study. * Best corrected visual acuity of 55 or greater in each eye as measured by ETDRS (letters read method). * Able and willing to comply with study protocol and follow protocol instructions. * Able to avoid any of the topical ocular or systemic excluded medications during the entire study period. * At least 1 year subject-reported or physician-diagnosed history (prior to Screen Visit) of allergic conjunctivitis during the ragweed season. * Positive skin prick test for short ragweed allergen within 12 months prior to Screen Visit. * Significant staff-assessed ocular redness in at least one region in each eye within the 3 hour period of allergen exposure in the EEC (Screen Visits). * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for at least 1 week following the last dose of investigational product. * Presence of any ocular infection, history of ocular Herpes (simplex or zoster) or adenoviral infection in either eye. * History of any ocular infection, physician or subject diagnosed, within 30 days prior to Screen Visit. * Presence of glaucoma, past history of, or diagnosis of glaucoma or ocular hypertension. * Presence of blepharitis, active rosacea affecting the ocular adnexa, meibomian gland dysfunction, follicular conjunctivitis, intraocular inflammation, or preauricular lymphadenopathy or any other ophthalmic abnormality that may affect the study outcomes. * Corneal conditions affecting the corneal structure. * Unwilling to discontinue contact lens wear during the study period. * Any ocular surgery including ocular laser procedures within 1 year prior to Screen Visit. * Current or recent (\<6 months prior to Screen Visit) history of severe, unstable, or uncontrolled autoimmune, neurological, cardiovascular, hematological, hepatic, renal, psychological, respiratory, gastrointestinal and/or immunological disease or evidence of other diseases based upon a review of medical history and/or physical examination that, in the opinion of the Investigator, would preclude safe subject participation in the study. * Receiving treatment for anxiety and/or depression at the Screen Visit; any history of suicide attempt. * Participation in any investigational study within 30 days of Screen Visit or concomitantly with this study. * Known contraindications or hypersensitivities to any of the study medications or their components * Confirmed (by physician or optometrist) diagnosis of dry eye. * History of sensitivity or adverse reaction to steroids. * Known allergic reaction that is unresponsive to corticosteroids or non-steroidal anti-inflammatory drugs (NSAIDS). * Physician diagnosed asthma (except inactive childhood asthma and exercise-induced asthma). * Evidence of active inflammation in the eye as determined by the dilated fundus examination conducted at Screen C Visit. * Any corneal swelling or haze as determined by the slitlamp examination conducted at Screen C Visit. * Other protocol-defined exclusion criteria may apply.